Elisabeth Ejerblad

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Rasmussen, Bengt; Nilsson, Lars; Tobiasson, Magnus; Jaedersten, Martin et al.

Ingår i Genes, Chromosomes and Cancer, 2025

• DOI för Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide
• Ladda ner fulltext (pdf) av Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Creignou, Maria; Bernard, Elsa; Gasparini, Alessandro; Tranberg, Anna et al.

Ingår i Journal of Internal Medicine, s. 53-67, 2024

• DOI för Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
• Ladda ner fulltext (pdf) av Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Tobiasson, Magnus; Pandzic, Tatjana; Illman, Johanna; Nilsson, Lars et al.

Ingår i Journal of Clinical Oncology, 2024

• DOI för Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective

Moreno Berggren, Daniel; Garelius, Hege; Willner Hjelm, Petter; Nilsson, Lars et al.

Ingår i Leukemia, s. 1103-1112, 2023

• DOI för Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective
• Ladda ner fulltext (pdf) av Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective

MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients

Larfors, Gunnar; Moreno Berggren, Daniel; Garelius, Hege; Nilsson, Lars et al.

Ingår i Leukemia Research, 2023

• DOI för MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients
• Ladda ner fulltext (pdf) av MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Rasmussen, Bengt; Nilsson, Lars; Tobiasson, Magnus; Jaedersten, Martin et al.

Ingår i Genes, Chromosomes and Cancer, 2025

• DOI för Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide
• Ladda ner fulltext (pdf) av Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Creignou, Maria; Bernard, Elsa; Gasparini, Alessandro; Tranberg, Anna et al.

Ingår i Journal of Internal Medicine, s. 53-67, 2024

• DOI för Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
• Ladda ner fulltext (pdf) av Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Tobiasson, Magnus; Pandzic, Tatjana; Illman, Johanna; Nilsson, Lars et al.

Ingår i Journal of Clinical Oncology, 2024

• DOI för Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective

Moreno Berggren, Daniel; Garelius, Hege; Willner Hjelm, Petter; Nilsson, Lars et al.

Ingår i Leukemia, s. 1103-1112, 2023

• DOI för Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective
• Ladda ner fulltext (pdf) av Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective

MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients

Larfors, Gunnar; Moreno Berggren, Daniel; Garelius, Hege; Nilsson, Lars et al.

Ingår i Leukemia Research, 2023

• DOI för MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients
• Ladda ner fulltext (pdf) av MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients

"Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Rasmussen, Bengt; Gohring, Gudrun; Bernard, Elsa; Nilsson, Lars et al.

Ingår i Leukemia, s. 1436-1439, 2022

• DOI för "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
• Ladda ner fulltext (pdf) av "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study

Lindholm, C.; Olofsson, E.; Creignou, M.; Nilsson, L. et al.

Ingår i Bone Marrow Transplantation, s. 598-606, 2022

• DOI för Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study
• Ladda ner fulltext (pdf) av Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population

Wedge, Eileen; Hansen, Jakob Werner; Dybedal, Ingunn; Creignou, Maria et al.

Ingår i Transplantation and Cellular Therapy, s. 9910-991000000000, 2021

• DOI för Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population

Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes

Larfors, Gunnar; Moreno Berggren, Daniel; Garelius, Hege; Jadersten, Martin et al.

Ingår i European Journal of Haematology, s. 219-228, 2021

• DOI för Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes
• Ladda ner fulltext (pdf) av Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study

Moreno Berggren, Daniel; Kjellander, Matilda; Backlund, Ellen; Engvall, Marie et al.

Ingår i British Journal of Haematology, s. 474-483, 2021

• DOI för Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study
• Ladda ner fulltext (pdf) av Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Birgegård, Gunnar; Samuelsson, Jan; Ahlstrand, Erik; Ejerblad, Elisabeth et al.

Ingår i European Journal of Haematology, s. 235-240, 2019

• DOI för Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register

Berggren, Daniel Moreno; Folkvaljon, Yasin; Engvall, Marie; Sundberg, Johan et al.

Ingår i British Journal of Haematology, s. 614-627, 2018

• DOI för Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register

Targeted Sequencing of A Cohort Of 385 Patients With Myelodysplastic Syndromes: A Multicenter, Population-Based Study From Sweden

Creignou, M.; Ejerblad, Elisabeth; Antunovic, P.; Garelius, H. et al.

Ingår i Leukemia Research, 2017

METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE

McPherson, S.; McCourt, P.; Ejerblad, Elisabeth; Zweegman, S. et al.

Ingår i Haematologica, s. 278-279, 2017

Validation Of Prognostic Scoring Systems For Myelodysplastic Syndromes In The Swedish Mds-Register

Berggren, Daniel Moreno; Folkvaljon, Y.; Engvall, M.; Sundberg, J. et al.

Ingår i Haematologica, s. 243-243, 2016

Recent results of allogeneic stem cell transplantation for myelofibrosis using reduced intensity conditioning - the Swedish experience

Lenhoff, S.; Dreimane, A.; Ejerblad, Elisabeth; Isaksson, C. et al.

Ingår i Bone Marrow Transplantation, 2015

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Andersen, Christen Lykkegaard; Bjorn, Mads Emil; McMullin, Mary Frances; Harrison, Claire et al.

Ingår i Leukemia Research, s. 816-821, 2014

• DOI för Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Influence of IL-28B and IL-6 Genetic Polymorphism on IFN-ALFA Treatment Outcome in Patients with Polycythemia Vera and Essential Trombocythemia

Lindgren, M.; Samuelsson, J.; Nilsson, L.; Knutsen, H. et al.

Ingår i Haematologica, s. 130-131, 2014

A Retrospective Cohort Study of Interferon-alpha Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

Lindgren, Marie; Samuelsson, Jan; Nilsson, Lars; Knutsen, Havar et al.

Ingår i Blood, 2014

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Ejerblad, Elisabeth; Kvasnicka, Hans M; Thiele, Jürgen; Andreasson, Björn et al.

Ingår i Hematology, s. 8-13, 2013

• DOI för Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

Abelsson, Johanna; Andreasson, Bjorn; Samuelsson, Jan; Hultcrantz, Malin et al.

Ingår i Leukemia and Lymphoma, s. 2226-2230, 2013

• DOI för Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

Andersen, Christen L.; McMullin, Mary F.; Ejerblad, Elisabeth; Zweegman, Sonja et al.

Ingår i British Journal of Haematology, s. 498-508, 2013

• DOI för A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

Obesity and Risk for Chronic Renal Failure.

Ejerblad, Elisabeth; Fored, CM; Lindblad, P; Fryzek, J et al.

Ingår i J Am Soc Nephrol, 2006